Bank of America
TRVI icon

Bank of America’s Trevi Therapeutics TRVI Stock Holding History

Bank of America’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5M Buy
1,216,955
+122,104
+11% +$1.37M ﹤0.01% 2649
2025
Q4 		$13.7M Sell
1,094,851
-741,988
-40% -$8.58M ﹤0.01% 2600
2025
Q3 		$16.8M Buy
1,836,839
+739,342
+67% +$5.54M ﹤0.01% 2780
2025
Q2 		$6M Buy
1,097,497
+965,732
+733% +$6.01M ﹤0.01% 3706
2025
Q1 		$829K Buy
131,765
+86,298
+190% +$412K ﹤0.01% 5356
2024
Q4 		$187K Sell
45,467
-2,280
-5% -$7.3K ﹤0.01% 6149
2024
Q3 		$159K Buy
47,747
+3,463
+8% +$10.3K ﹤0.01% 6118
2024
Q2 		$132K Buy
44,284
+22,308
+102% +$62K ﹤0.01% 6109
2024
Q1 		$75.8K Sell
21,976
-20,016
-48% -$44.7K ﹤0.01% 6378
2023
Q4 		$56.3K Buy
41,992
+13,299
+46% +$20.1K ﹤0.01% 6561
2023
Q3 		$62.5K Sell
28,693
-8,897
-24% -$20.1K ﹤0.01% 6427
2023
Q2 		$89.8K Buy
+37,590
New +$94.7K ﹤0.01% 6245
2023
Q1 		– Sell
-92
Closed -$178 – 8274
2022
Q4 		$178 Buy
+92
New +$181 ﹤0.01% 7565
2021
Q2 		– Sell
-16
Closed – – 8092
2021
Q1 		$0 Buy
+16
New +$47 ﹤0.01% 7775
2020
Q4 		– Sell
-179
Closed -$1K – 7371
2020
Q3 		$1K Buy
179
+139
+348% +$653 ﹤0.01% 6793
2020
Q2 		$0 Buy
+40
New +$141 ﹤0.01% 7134
2019
Q4 		– Sell
-1
Closed – – 7400
2019
Q3 		$0 Buy
+1
New +$5 ﹤0.01% 7504

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bank of America's TRVI Position: Q1 2026 in Review

Bank of America increased its Trevi Therapeutics (TRVI) stake by 11% in Q1 2026, buying an estimated $1.37M and bringing the position to 1,216,955 shares worth $14.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2649.

Bank of America first reported a position in TRVI in Q3 2019 and has held it in 17 quarters since. The position peaked at $16.8M in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Bank of America held 1,216,955 shares of Trevi Therapeutics worth $14.5M as of Q1 2026.
  • Bank of America bought 122,104 Trevi Therapeutics shares in Q1 2026, an estimated $1.37M.
  • Trevi Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2649 holding.
  • Bank of America first reported a position in Trevi Therapeutics in Q3 2019 and has held it in 17 quarters since.
  • Bank of America's Trevi Therapeutics position peaked at $16.8M in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.